

Phone: +45 3545 4534

Fax: +45 3545 4524

Patient:

Name: Sur, First
CPR: DDMMYY-CTRL
Weight: 36 kg

This Busilvex infusion (no 1 of 4)

Date: 6-7 April 2016
Duration: 3,27 hours
Dose: 115 mg

▣ Busilvex dose suggested by patient weight:

Dose: 115,2 mg/day

***/§ Busulfan exposure during this infusion:**

AUC_{0-∞}: 17,27 mg*h/L
C_{ss}: 719,5 ng/ml

Recommended dose for each of the subsequent 3 infusion(s):

128,2 mg/infusion Total AUC target 75 mg*h/L
161,5 mg/infusion Total AUC target 90 mg*h/L


(Total AUC of previous 0 infusion(s): 0,00 mg*h/L)

* Calculations made with a two-compartment model assuming first-order elimination and 24 hour dosing intervals.

§ AUC: Area Under Curve; C_{ss}: Steady-state plasma Busulfan concentration (24 hour infusion interval).

Doses are estimated from the Bu doses and AUCs from this and previous infusions.

▣ <9 kg: 4 mg kg/d; =9 to <16 kg: 4,8 mg kg/d; =16 to =23 kg: 4,4 mg kg/d; >23 to =34 kg: 3,8 mg kg/d; >34 kg: 3,2 mg kg/d.



Interpretation of AUC (total over 4 days) in standard situations:

- A) >95 mg*h/L: Toxic level. Increased risk of VOD. Consider decreasing the dose.
- B) 85-95 mg*h/L: Appropriate for malignant disease (with normal liver function).
- C) 50-85 mg*h/L: Appropriate for non-malignant disease.
- D) <50 mg*h/L: Sub-myeloablative level. Consider increasing the dose.

Exposure measures:

AUC = 5000 μmol*min/L corresponds to AUC = 20,53 mg*h/L or C_{ss} = 855,2 ng/ml

Analysed on 7 April 2016 by Jacob Nersting

Comments: None